[{"address1": "Gooimeer 2-35", "city": "Naarden", "zip": "1411 DC", "country": "Netherlands", "phone": "31 35 206 2971", "website": "https://www.newamsterdampharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Michael Harvey Davidson FACC, Facp., M.D.", "age": 68, "title": "CEO, President, Executive Board Member & Director", "yearBorn": 1956, "fiscalYear": 2024, "totalPay": 1122237, "exercisedValue": 0, "unexercisedValue": 51427864}, {"maxAge": 1, "name": "Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.", "age": 70, "title": "Founder, Chief Scientific Officer, Member of Executive Board & Director", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 813077, "exercisedValue": 4094829, "unexercisedValue": 35092304}, {"maxAge": 1, "name": "Mr. Mayur Amrat Somaiya", "age": 50, "title": "Chief Financial Officer", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 841238, "exercisedValue": 0, "unexercisedValue": 3954412}, {"maxAge": 1, "name": "Mr. Douglas F. Kling", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 913742, "exercisedValue": 0, "unexercisedValue": 17441960}, {"maxAge": 1, "name": "Ms. Juliette  Audet M.B.A., M.Sc.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 653039, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Louise  Kooij", "age": 48, "title": "Chief Accounting Officer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Philippe", "title": "Executive VP &Head of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  Rambo", "title": "Executive Vice President of Marketing", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryellen  McQuade", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marc  Ditmarsch M.D.", "age": 57, "title": "Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 17.47, "open": 17.35, "dayLow": 17.1905, "dayHigh": 17.69, "regularMarketPreviousClose": 17.47, "regularMarketOpen": 17.35, "regularMarketDayLow": 17.1905, "regularMarketDayHigh": 17.69, "payoutRatio": 0.0, "beta": -0.002, "forwardPE": -9.269841, "volume": 344493, "regularMarketVolume": 344493, "averageVolume": 991242, "averageVolume10days": 482600, "averageDailyVolume10Day": 482600, "bid": 17.45, "ask": 17.59, "bidSize": 1, "askSize": 1, "marketCap": 1924011392, "fiftyTwoWeekLow": 14.06, "fiftyTwoWeekHigh": 27.29, "priceToSalesTrailing12Months": 42.227497, "fiftyDayAverage": 19.847, "twoHundredDayAverage": 19.884575, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1090266112, "profitMargins": 0.0, "floatShares": 53941411, "sharesOutstanding": 109818000, "sharesShort": 5069436, "sharesShortPriorMonth": 4342156, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0462, "heldPercentInsiders": 0.00358, "heldPercentInstitutions": 1.03418, "shortRatio": 4.04, "shortPercentOfFloat": 0.0694, "impliedSharesOutstanding": 109818000, "bookValue": 7.01, "priceToBook": 2.4992867, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -241598000, "trailingEps": -2.56, "forwardEps": -1.89, "enterpriseToRevenue": 23.929, "enterpriseToEbitda": -6.189, "52WeekChange": -0.1911357, "SandP52WeekChange": 0.07995045, "quoteType": "EQUITY", "currentPrice": 17.52, "targetHighPrice": 56.256256, "targetLowPrice": 38.917686, "targetMeanPrice": 46.94824, "targetMedianPrice": 45.030697, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 9, "totalCash": 834190016, "totalCashPerShare": 7.596, "ebitda": -176176000, "totalDebt": 448000, "quickRatio": 8.001, "currentRatio": 8.075, "totalRevenue": 45563000, "debtToEquity": 0.059, "revenuePerShare": 0.483, "returnOnAssets": -0.18186001, "returnOnEquity": -0.46199, "grossProfits": 45563000, "freeCashflow": -43394624, "operatingCashflow": -158564000, "revenueGrowth": 14.905, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -3.38467, "financialCurrency": "USD", "symbol": "NAMS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NGM", "messageBoardId": "finmb_685404834", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "NewAmsterdam Pharma Company N.V", "corporateActions": [], "postMarketTime": 1745613284, "regularMarketTime": 1745611200, "marketState": "CLOSED", "longName": "NewAmsterdam Pharma Company N.V.", "regularMarketChangePercent": 0.2862115, "regularMarketPrice": 17.52, "fiftyDayAverageChange": -2.3269997, "fiftyDayAverageChangePercent": -0.11724692, "twoHundredDayAverageChange": -2.3645744, "twoHundredDayAverageChangePercent": -0.118915014, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2022-11-23", "prevName": "Frazier Lifesciences Acquisition Corporation", "nameChangeDate": "2025-04-25", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612881000000, "postMarketChangePercent": 0.0, "postMarketPrice": 17.52, "postMarketChange": 0.0, "regularMarketChange": 0.050001144, "regularMarketDayRange": "17.1905 - 17.69", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 991242, "fiftyTwoWeekLowChange": 3.46, "fiftyTwoWeekLowChangePercent": 0.24608819, "fiftyTwoWeekRange": "14.06 - 27.29", "fiftyTwoWeekHighChange": -9.77, "fiftyTwoWeekHighChangePercent": -0.3580066, "fiftyTwoWeekChangePercent": -19.113571, "earningsTimestamp": 1740576600, "earningsTimestampStart": 1746448200, "earningsTimestampEnd": 1746793800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.56, "epsForward": -1.89, "epsCurrentYear": -1.72812, "priceEpsCurrentYear": -10.1381855, "displayName": "NewAmsterdam Pharma Company", "trailingPegRatio": null, "__fetch_time": "2025-04-26"}]